Loading Events

Upcoming Events

Events Search and Views Navigation

Event Views Navigation

May 2019

Cycle 2: Broad PCORI Funding Announcements

May 29

Sponsor: Patient-Centered Outcomes Research Institute
LOI Due Date: May 29, 2019 by 5 pm ET
Application Due Date: September 4, 2019 by 5 pm
Award: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; and Improving Healthcare Systems: $3 million; Communication & Dissemination Research: $2 million. Maximum project period is 3 years.

Find out more »

June 2019

Training Institute for Dissemination and Implementation Research in Health

June 23 @ 8:00 pm

Sponsors: NIH, US Department of Veterans Affairs, US Department of Health and Human Services
Application Due Date: June 23, 2019, by 8:00 PM EDT
Award and Eligibility: This training is designed for doctoral-level investigators at any career stage interested in conducting D&I research.

Find out more »

Society for Research on Hydrocephalus and Spina Bifida Annual Conference

June 26 - June 29
Canary University Hospital, Carretera Cuesta Taco
Santa Cruz de Tenerife, 38320 Spain

The 63rd Annual Meeting of our Society will continue our traditional focus and personable approach. The program will focus mainly on research in hydrocephalus, neural tube defects, and spina bifida, with the days and times designated for each topic contingent upon the abstracts submitted. We will provide leisure time to visit Tenerife Island and enjoy its rich gastronomy, and we are planning special sessions on brain development and transitional care for patients with hydrocephalus and spina bifida.

Find out more »

July 2019

Cycle 2: NIH R01 and U01

July 5

DUE DATE: JULY 5, 2019
NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.

Find out more »

Cycle 4: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

July 7

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 7, 2019
Application Due Date: August 9, 2019
Award: Actual needs; applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II.

Find out more »

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 12

LOI DUE JULY 12, 2019
Drug Discovery Program
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

August 2019

Cycle 2: Health Services Research Pipeline Grant

August 5

Sponsor: Foundation for Physical Therapy Research
Application Deadline: August 5, 2019
Award and Eligibility: One Health Services Research Pipeline Grant (HSRPG) of $40,000 is to be awarded to support research that examines mechanisms by which patients obtain physical therapy-related health care, how much such care costs, and what outcomes are observed in these patients. Research efforts should focus on the identification of the most effective ways to organize, manage, finance, and deliver high quality physical therapy-related care while potentially reducing medical errors and improving safety for patients.

Find out more »

October 2019

Cycle 3: Whitehall Foundation Grants-in-Aids

October 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award:  Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Cycle 3: Whitehall Foundation Research Grants

October 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

Cycle 4: Alzheimer’s Drug Discovery Foundation

October 11

LOI DUE OCTOBER 11, 2019
Drug Discovery Program
The Drug Discovery RFP supports novel drug programs and repurposed/repositioned programs. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

November 2019

Cycle 3: Prevention Research in Mid-Life Adults (R01)

November 5

Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.

Find out more »

December 2019

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

January 2020

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

January 1, 2020

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years

Find out more »

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »
+ Export Events